Megan Boston - 18 Nov 2025 Form 4 Insider Report for Benitec Biopharma Inc. (BNTC)

Role
Chief Financial Officer, Director
Signature
/s/ Megan Boston
Issuer symbol
BNTC
Transactions as of
18 Nov 2025
Net transactions value
$0
Form type
4
Filing time
20 Nov 2025, 17:35:36 UTC
Previous filing
11 Dec 2024
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Boston Megan Chief Financial Officer, Director C/O BENITEC BIOPHARMA INC., 3940 TRUST WAY, HAYWARD /s/ Megan Boston 20 Nov 2025 0001808923

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BNTC Options (right to buy) Award $0 +200,000 $0.000000 200,000 18 Nov 2025 Common Stock 200,000 $13.53 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock options will vest in 16 substantially equal quarterly installments commencing on March 31, 2026.